Dren Bio closed an oversubscribed $350 million private financing round to advance dibotatug (DR-01), a CD94-targeting monoclonal antibody designed to deplete pathogenic cytotoxic cells while preserving broader immune function. The clinical-stage biotech said the funding will support late-stage development, regulatory submission, and a planned commercial launch. Dren’s lead clinical programs target rare blood cancers—cytototoxic T-cell lymphoma and large granular lymphocytic leukemia (LGLL)—conditions with limited treatment options. The company framed its antibody mechanism as a selective immunologic approach that could avoid broader immune suppression seen with less targeted strategies. The financing was co-led by Juvia Group and Lightspeed Venture Partners, with participation from investors including Mirae Asset Capital Life Science, General Catalyst, OrbiMed, and General Catalyst. Existing backers such as 8VC, SR One, Taiho Ventures, and OrbiMed also participated. For the broader sector, the round reinforces how private markets continue to reward late-stage progress in rare disease oncology when the mechanism is framed around selectivity and a defined regulatory/commercial pathway.